RESEARCH ARTICLE

Accuracy of Determine TB-LAM Ag to detect TB in HIV infected patients associated with diagnostic methods used in Brazilian public health units

Aline Benjamin1*, Solange Cesar Cavalcante1, Leda Fátima Jamal2, Denise Arakaki-Sanchez3, Josué Nazareno de Lima3, Jose Henrique Pilotto4,6, Francisco Ivanildo de Oliveira Junior6, Tâmara Newman Lobato Souza6, Maria Cristina Lourenço7, Maeve Brito de Mello6, Pedro Emmanuel Alvarenga Americano do Brasil9, Draurio Barreira10, Valeria Rolla1

1 Clinical Research Laboratory on Mycobacteria, National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, 2 STD/AIDS Reference and Training Center, Health Secretariat of State of São Paulo, Brazil, 3 National Tuberculosis Program, Ministry of Health, Brasilia, Brazil, 4 STD/AIDS Service, Nova Iguaçu General Hospital, Rio de Janeiro, Brazil, 5 Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, 6 Institute of Infectious Disease Emilio Ribas, São Paulo, Brazil, 7 Bacteriology and Bioassay Laboratory, National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, 8 Pan American Health Organization, Washington DC, United States of America, 9 Clinical Research Laboratory on Immunization and Surveillance in Health, National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, 10 Unitaid, Geneva, Switzerland

* aline.benjamin@ini.fiocruz.br

Abstract

Background

Determine TB-LAM Ag (LAM) is a point-of-care test developed to diagnose tuberculosis (TB). The aim of this study was to evaluate the diagnostic performance of LAM in people living with HIV using Brazilian public health network algorithm for TB diagnosis.

Methods and findings

A cross-sectional study design was used to enroll 199 adult patients in two sites in Rio de Janeiro and two in São Paulo. The study enrolled HIV-infected patients with CD4 counts ≤200 cells/mm³ (in the Alere PIMA CD4 assay at study screening), patients coughing for at least 2 weeks or presenting a chest radiography suggestive of TB. LAM, in conjunction with sputum smear microscopy or Xpert MTB/RIF (Xpert) as compared to Mycobacterium tuberculosis culture, which was used as a reference standard. TB prevalence was 24.6%. Overall accuracy of LAM was 79.9% (73.8%-84.9%), positive and negative predictive values were 62.2% (46.1%-75.9%) and 84% (77.5%-88.8%), respectively. The overall LAM sensitivity was 46.9% (33.7%-60.6%) and specificity was 90.7% (84.9%-94.4%). The best performance of LAM was observed among patients with CD4 counts ≤50 cells/mm³ (sensitivity = 70.4% and specificity = 85.9%). When 2 respiratory smears were used in conjunction with LAM, sensitivity increased 22%, as compared to just 2 smears. Furthermore, LAM when
used in conjunction with two respiratory smears, was as sensitive as compared to a single one. However, no improvement in TB diagnosis occurred when LAM was used with Xpert as compared to Xpert alone. Among 14 LAM false positive tests, Non-Tuberculosis Mycobacteria were isolated in three cases.

Conclusion

LAM is a point of care test that increased TB diagnosis in immunosuppressed HIV-infected patients when used in conjunction with smear microscopy, but not when used with Xpert in Brazilian public health network sites. Use of LAM test should be considered in settings where immunosuppressed HIV patients need rapid TB diagnosis.

Introduction

Tuberculosis (TB) diagnosis continues to be a challenge in people living with HIV (PLHIV) since immunosuppression results in atypical images on the chest X-ray [1,2] and paucibacillary disease. This often leads to negative smear microscopy [3,4] and delayed diagnosis as *Mycobacterium tuberculosis* (Mtb) culture is slow to grow.

Brazil used a TB diagnostic algorithm based on smear microscopy and Mycobacterial culture until 2014 [5], when it was modified to incorporate Xpert MTB/RIF (Xpert) into the public health system [6]. Since then, for PLHIV, Brazilian public health laboratories use either: a) Xpert, culture and drugs sensitivity tests (DST) for new TB cases or b) two sputum smears, Xpert, culture and DST for retreatment of TB cases.

Determine TB LAM Ag (LAM) detects lipoarabinomannan, a glycolipid from Mycobacteria wall that is eliminated in the patient’s urine. The overall sensitivity is low [7,8], but the test does increase TB diagnosis in HIV immunosuppressed patients [9]. The World Health Organization (WHO) advises that LAM should only be used on PLHIV with symptoms suggestive of pulmonary and/or extrapulmonary TB, with CD4 \( \leq 100 \) cells/mm\(^3\) or in those seriously ill if CD4 cell counts are unavailable [10].

The aim of this study was to evaluate the diagnostic performance of LAM in PLHIV with CD4 counts \( \leq 200 \) cell/mm\(^3\), when used in conjunction with smear microscopy or Xpert, compared to Mtb culture to determine if LAM should be incorporated into the Brazilian TB diagnosis algorithm for PLHIV in the public health system.

Materials and methods

Ethics statement

This study was approved by the following Institutional Review Boards: National Institute of Infectious Diseases Evandro Chagas, Center for Reference and Training STD/AIDS, Nova Iguaçu General Hospital and Institute of Infectious Disease Emilio Ribas and by National Research Ethics Committee (CAAE number 439.001).

Study design

This was a cross-sectional, pragmatic multicenter study with consecutive inclusion of patients suspected of TB attended at 2 sites in Rio de Janeiro (National Institute of Infectious Diseases Evandro Chagas and Nova Iguaçu General Hospital) and 2 sites in São Paulo (Institute of Infectious Disease Emilio Ribas and Center for Reference and Training STD/AIDS). All four sites are public HIV reference health units.
Participants

Patients were initially screened to detect signs and symptoms of TB and HIV. Chest X-ray was requested for those without a previous exam in the last 15 days before enrollment. Participants were also submitted to a rapid CD4 cell count through Alere PIMA Analyzer. At least one respiratory sample was provided to perform smear microscopy and Mycobacterial culture. Hemoculture and other specimens cultures were done according to patients’ signs and symptoms. During this study, Xpert was incorporated into Brazilian TB diagnosis algorithm and was included in the protocol after an amendment to the original one.

Patients were enrolled if they were 18 years old or more, HIV-positive, signed an informed consent, had cough for at least 2 weeks or presented a chest radiography suspected of TB and had CD4 counts $\leq$ 200 cells/mm$^3$. Patients were excluded if they were pregnant, did not provide urine, failed to provide at least one respiratory sample or had initiated TB treatment 30 days before study entry.

Study procedures

All enrolled participants provided a fresh urine sample for LAM detection. The results were independently read by two nurses and photos were taken for future comparisons.

Chest X-rays showing upper lobe opacity, lower lobe upper segment opacity, milliary pattern, mediastinal adenopathy, pleural effusion or cavitation were considered suggestive of TB.

TB diagnostic tests were performed by a certified public bacteriology laboratory for each site involved. Respiratory samples, as well as other suspected site samples, were processed following their own standardized practices. Laboratories staffs were blinded to patient’s clinical data and LAM results. Acid fast stain were done using Ziehl-Neelsen method and Mycobacteria load was reported as negative, scarce bacilli, +, ++ and +++ according to Brazilian TB Guidelines [11]. At the Rio de Janeiro sites, Mycobacterial culture was performed using Lowenstein-Jensen medium and MGIT Mycobacterial Growth Indicator Tubes (BD Diagnostics, USA), while at São Paulo sites only MGIT was performed. Xpert, LAM and Alere PIMA CD4 assays were performed according to manufacturers’ instructional package inserts. Respiratory sample diagnostic routine and LAM test were performed in parallel.

A patient was considered with TB diagnosis if any culture (LJ or MGIT) of any respiratory or no respiratory sample resulted in Mtb isolation.

All clinical and laboratorial data were recorded through Research Electronic Data Capture and data was analyzed using R-project, version 3.4.3. Descriptive analyzes were used for socio-demographic and clinical characteristics. Diagnostic accuracy measurements of sensitivity, specificity and predictive values were estimated with 95% confidence interval in overall population and stratified by CD4 cell counts ($\leq 50$, 51–100 and 101–200), with Mtb culture as the reference standard. The tests combinations were conducted in parallel, which means subjects were classified as positive when at least one of them was positive, even if one of the tests was absent.

Sample size calculation

Since there was little information regarding TB diagnosis when adding LAM to existing testing algorithms, the sample size for the study was based on several considerations. Since smear sensitivity was expected to be between 50% and 60% an increase of sensitivity between 20% and 40% was expected when adding LAM to smear. At a parsimony situation, a non-overlapping 95% binomial confidence interval could be observed when a sensitivity increases from 55% to 85% and tested with a sample size of 40. As the inclusion strategy was to be consecutive, and
TB prevalence was expected to be between 30% and 40% at the lower CD4 strata, a reasonable sample size would be between 100 and 133.

Although Xpert was unavailable at Brazil in the beginning of the study, its’ design allowed the analyses of this test in TB diagnosis algorithm.

**Results**

There were 278 patients screened and 199 enrolled between August, 2014 and December, 2015. Among those not eligible 25 were HIV negative, one had no cough neither suspected chest X-ray, 45 had CD4 counts >200 cells/mm³, one could not provide urine, six did not provide a respiratory sample and one used TB drugs previously (S1 Fig). Of the 199 enrolled patients, 127 were men and 72 were women, the mean (standard deviation) age was 39.06 (±9.95) years and the median CD4 count was 42 (IQR 19–82) cells/mm³ at enrollment. There was no difference regarding clinical characteristics between LAM negative and positive patients, except for CD4 counts. Most LAM positive patients (83.78%) had a CD4 count ≤50 cells/mm³ (Table 1). Eighty-nine patients presented chest images suggestive of TB and only 8/89 presented cavitation—the most typical pulmonary abnormality observed in TB. Among these 8 patients, 2 had CD4 ≤50 cells/mm³, 2 had CD4 between 51 and 100 cells/mm³ and the other 4 had CD4 between 101 and 200 cells/mm³.

Most patient could provide spontaneous sputum for the first respiratory sample, but 54.3% didn’t collected the second sample. More detailed information about diagnostic tests are in S1 Table.

TB prevalence was 18.6% and 24.6% according to LAM and Mtb culture, respectively. LAM’s overall accuracy was 79.9% (73.8%-84.9%). Positive and negative predictive values were 62.2% (46.1%-75.9%) and 84% (77.5%-88.8%), respectively. The overall sensitivity and specificity of LAM was 46.9% (33.7%-60.6%) and 90.7% (84.9%-94.4%), respectively (Fig 1).

The best performance of LAM was observed among patients with CD4 counts ≤50 cells/mm³, where sensitivity was 70.4% (51.5%-84.1%) and specificity was 85.9% (76.9%-91.7%). When two smears microscopy were combined with LAM, sensitivity was increased by 22% when compared to two smears alone, achieving a sensitivity close to Xpert. Furthermore, LAM combined with two smears was as sensitive as when combined to a single smear. LAM did not add sensitivity when combined to Xpert when compared to Xpert alone (Fig 2). For patients with higher CD4 cell counts, LAM’s sensitivity was too low to explore combinations either with Xpert or sputum smear.

There were 14 false positive LAM results. In three cases, Non-Tuberculosis Mycobacteria grew in culture.

**Discussion**

In our study, the accuracy of LAM was low in overall population, but was better in patients with low CD4 cell counts, as already reported [9,12–14]. The greatest benefit of LAM was observed in patients with CD4 counts ≤50 cells/mm³. LAM increased TB diagnosis when associated with smear microscopy, achieving a sensitivity close to Xpert, indicating what could be an interesting option for settings with poor diagnosis infrastructure. In addition, LAM could be combined with a single smear, without decreasing sensitivity, speeding up the diagnosis. LAM did not improve TB diagnosis when associated with Xpert, as observed by other authors [9]. However, Xpert was included in the Brazilian diagnosis algorithm during the study and only 73.2% of those with CD4 ≤50 cells/mm³ were tested for Xpert. The lower number of cases could have influenced these analyses.
Table 1. Absolute and relative frequencies of clinical characteristics at TB investigation by LAM result (relative frequencies are in parenthesis, except as otherwise indicated).

|                        | LAM Negative | LAM Positive | Total | Statistic Test | P Value |
|------------------------|--------------|--------------|-------|----------------|---------|
| **Total**              | 162          | 37           | 199   |                |         |
| **Gender**             |              |              |       |                |         |
| Male                   | 100 (61.73)  | 27 (72.97)   | 127 (63.82) | Chisq. (1 df) = 1.198 | 0.274  |
| Female                 | 62 (38.27)   | 10 (27.03)   | 72 (36.18) |                |         |
| **Age**                |              |              |       |                |         |
| Mean (SD)              | 39.76 (10.01)| 36.00 (9.16)| 39.06 (9.95) | t-test (198 df) = 2.090 | 0.038  |
| CD4 counts median (IQR)| 51 (22.3,90.8)| 25 (15.39)| 42 (19.82) | Rannksum test | < 0.001 |
| CD4                    |              |              |       |                |         |
| [0,50]                 | 81 (50.00)   | 31 (83.78)   | 112 (56.28) | Chi-square (2df) = 14.603 | < 0.001 |
| (50,100]               | 47 (29.01)   | 5 (13.51)    | 52 (26.13) |                |         |
| (100,200]              | 34 (20.99)   | 1 (2.70)     | 35 (17.59) |                |         |
| **Chest Xray suggestive of TB?** |              |              |       |                |         |
| No                     | 66 (43.42)   | 12 (34.29)   | 78 (41.71) | Chi-square (2df) = 2.961 | 0.228  |
| Yes                    | 68 (44.74)   | 21 (60.00)   | 89 (47.59) |                |         |
| **Inespecific abnormalities** | 18 (11.84)   | 2 (5.71)     | 20 (10.70) |                |         |
| **Night sweats since beginning of symptoms?** |              |              |       |                |         |
| No                     | 66 (40.74)   | 10 (27.03)   | 76 (38.19) | Fisher’s exact test | 0.137  |
| Yes                    | 96 (59.26)   | 27 (72.97)   | 123 (61.81) |                |         |
| **Dyspnoea since beginning of symptoms?** |              |              |       |                |         |
| No                     | 46 (28.40)   | 10 (27.03)   | 56 (28.14) | Fisher’s exact test | 1       |
| Yes                    | 116 (71.60)  | 27 (72.97)   | 143 (71.86) |                |         |
| **Cough since beginning of symptoms?** |              |              |       |                |         |
| No                     | 9 (5.56)     | 4 (10.81)    | 13 (6.53)  | Fisher’s exact | 0.268  |
| Yes                    | 153 (94.44)  | 33 (89.19)   | 186 (93.47) |                |         |
| **Hemoptysis since beginning of symptoms?** |              |              |       |                |         |
| No                     | 134 (82.72)  | 33 (89.19)   | 167 (83.92) | Fisher’s exact | 0.745  |
| Yes                    | 24 (14.81)   | 4 (10.81)    | 28 (14.07) |                |         |
| Don’t know             | 4 (2.47)     | 0 (0.00)     | 4 (2.01)   |                |         |
| **Chest pain since beginning of symptoms?** |              |              |       |                |         |
| No                     | 68 (41.98)   | 17 (45.95)   | 85 (42.71)  | Fisher’s exact | 0.768  |
| Yes                    | 93 (57.41)   | 20 (54.05)   | 113 (56.78) |                |         |
| Don’t know             | 1 (0.62)     | 0 (0.00)     | 1 (0.50)   |                |         |
| **History of TB or TB previous treatment?** |              |              |       |                |         |
| No                     | 121 (74.69)  | 30 (81.08)   | 151 (75.88) | Fisher’s exact | 0.779  |
| Yes                    | 39 (24.07)   | 7 (18.92)    | 46 (23.12)  |                |         |
| Don’t know             | 2 (1.23)     | 0 (0.00)     | 2 (1.01)   |                |         |
| **TB clinical form**   |              |              |       |                |         |
| Pulmonary              | 18 (11.11)   | 16 (43.24)   | 34 (17.09)  | Fisher’s exact | 0.590  |
| Pleurpulmonary         | 2 (1.23)     | 0 (0.00)     | 2 (1.01)   |                |         |
| Disseminated           | 6 (3.70)     | 7 (18.92)    | 13 (6.53)   |                |         |
| Extrapulmonary         | 0 (0.00)     | 0 (0.00)     | 0 (0.00)   |                |         |

https://doi.org/10.1371/journal.pone.0221038.t001
One of the pillars for decreasing TB incidence is the rapid diagnosis [15]. Even today, a timely diagnosis is a limiting factor for early detection of TB, especially in developing countries where it is difficult for established laboratories to perform Mtb culture for high burden locations. Therefore, in many countries, the TB diagnosis is still based on smears and chest X-rays, which have low sensitivity and specificity. In PLHIV, the diagnosis is even more complex, since immunosuppression prevents the formation of granuloma, reducing the pulmonary cavities, resulting in atypical chest images [1,2]. Additionally, immunosuppressed individuals are paucibacillary and therefore more susceptible to have negative smear microscopy [3,4], which may lead to empirical or misleading treatments. Indeed, we observed a low number of patients with pulmonary cavity and a high number of negative smears in our study. Thus, the rapid TB diagnosis in immunodeficient patients is still a challenge.

| Test            | N  | Prev | Se [95% CI]         | Sp [95% CI]         |
|-----------------|----|------|---------------------|---------------------|
| LAM + Xpert     | 199| 0.246| 0.796 [0.664;0.885] | 0.887 [0.826;0.928] |
| Xpert           | 157| 0.261| 0.829 [0.687;0.915] | 0.948 [0.892;0.976] |
| LAM + 2 Smear   | 199| 0.246| 0.714 [0.576;0.822] | 0.893 [0.834;0.933] |
| LAM + 1 Smear   | 199| 0.246| 0.673 [0.534;0.788] | 0.900 [0.842;0.938] |
| LAM             | 199| 0.246| 0.469 [0.337;0.606] | 0.907 [0.849;0.944] |
| 2 Smear         | 199| 0.246| 0.571 [0.433;0.700] | 0.980 [0.943;0.993] |
| 1 Smear         | 199| 0.246| 0.510 [0.375;0.644] | 0.987 [0.953;0.996] |

Fig 1. Forest plot with sensitivity and specificity for different combination of tests in overall population.

https://doi.org/10.1371/journal.pone.0221038.g001
Xpert was a breakthrough in TB diagnosis due to its rapid and high accuracy, thereby decreasing time to initiate treatment [16]. Although Brazilian TB diagnosis algorithms have included Xpert since 2014, this test is not available throughout the country and is not a real point of care (PoC) test as most equipment are located in Mycobacteria laboratories. The most important criteria to allocate GeneXpert was regional TB incidence. Therefore, the machine was first provided to 92 municipalities. Additionally, nine others were provided for research purposes [17]. In low TB burden areas, smear microscopy is still the first method to diagnose TB in PLHIV and definitive diagnosis remains based on culture results.

There are limitations to making Xpert easily available in many health units. Xpert requires stable electric power and air conditioning, which can be an obstacle in low income countries. After one year of implementation, electrical power problems and local high temperature were common problems in Brazil [17]. In order to improve TB diagnosis in poor settings, a real” PoC” test is one which is quick, easy to perform and that could be used close to patients. LAM

| PIMA result = (100,200) | Se [95% CI] | Sp [95% CI] |
|---|---|---|
| Xpert | 0.571 [0.250,0.842] | 0.958 [0.798,0.993] |
| LAM + Xpert | 0.571 [0.250,0.842] | 0.929 [0.774,0.980] |
| LAM + 2 Smear | 0.429 [0.158,0.750] | 0.929 [0.774,0.980] |
| LAM + 1 Smear | 0.429 [0.158,0.750] | 0.929 [0.774,0.980] |
| LAM | 0.000 [0.000,0.354] | 0.964 [0.823,0.994] |
| 2 Smear | 0.429 [0.158,0.750] | 0.964 [0.823,0.994] |
| 1 Smear | 0.429 [0.158,0.750] | 0.964 [0.823,0.994] |

| PIMA result = (50,100) | Se [95% CI] | Sp [95% CI] |
|---|---|---|
| Xpert | 0.769 [0.497,0.918] | 0.968 [0.838,0.994] |
| LAM + Xpert | 0.667 [0.417,0.848] | 0.946 [0.823,0.985] |
| LAM + 2 Smear | 0.600 [0.357,0.802] | 0.973 [0.862,0.995] |
| LAM + 1 Smear | 0.467 [0.248,0.699] | 0.973 [0.862,0.995] |
| LAM | 0.267 [0.109,0.520] | 0.973 [0.862,0.995] |
| 2 Smear | 0.533 [0.301,0.752] | 1.000 [0.906,1.000] |
| 1 Smear | 0.400 [0.196,0.643] | 1.000 [0.906,1.000] |

| PIMA result = [0,50] | Se [95% CI] | Sp [95% CI] |
|---|---|---|
| Xpert | 0.952 [0.773,0.992] | 0.934 [0.843,0.974] |
| LAM + Xpert | 0.926 [0.766,0.979] | 0.847 [0.756,0.908] |
| LAM + 2 Smear | 0.852 [0.675,0.941] | 0.847 [0.756,0.908] |
| LAM + 1 Smear | 0.852 [0.675,0.941] | 0.859 [0.769,0.917] |
| LAM | 0.704 [0.515,0.841] | 0.859 [0.769,0.917] |
| 2 Smear | 0.630 [0.442,0.785] | 0.976 [0.918,0.994] |
| 1 Smear | 0.593 [0.407,0.755] | 0.988 [0.936,0.998] |

Fig 2. Forest plot with sensitivity and specificity for different combination of tests in different strata of CD4.

https://doi.org/10.1371/journal.pone.0221038.g002
combined with smear microscopy could increase TB diagnosis in Brazil, as Xpert is not fully available in all health facilities. In addition, urine is an easy to get specimen and LAM does not need biosafety protocols. It can even be performed at the bedside allowing for a TB diagnosis in different settings where PLHIV access health care. As PLHIV usually have difficulties in providing sputum, urine becomes a suitable biological sample for TB testing [3].

Severely immunodeficient patients may also have disease caused by NTM more frequently and there is a similarity between Mtb and other Mycobacteria lipoarabinomannam. Therefore, attention must be paid to cases of NTM diagnosed with a positive LAM. In this study, NTM were detected in three patients with positive LAM results. As we know, Mycobacterial cultures have limitations and can be affected by inadequate or insufficient sample, especially when patient has already started TB treatment. Therefore, positive LAM tests without a positive culture should be considered in some circumstances. In addition, recent studies had shown that LAM could potentially reduce mortality in PLHIV admitted to hospitals [18,19] due to an increase in TB diagnosis.

Our study has limitations as Xpert was included in the protocol latter, reducing the chance to fully observe its behavior in Brazilian algorithm. However, our straightness was to include more than 50% participants with very low CD4 counts allowing a good analysis on LAM performance in this specific group.

In conclusion, LAM is a real PoC test and should be used in combination with smear microscopy for TB diagnosis in immunosuppressed PLHIV. If CD4 counts are unknown, some clinical characteristics are indicative of immunosuppression and could predict a low CD4 count, being helpful to select which patients should be tested.

Although there have been previous Brazilian studies about LAM in leprosy [20,21] this is the first study using Determine TB LAM Ag conducted in Brazil using the national algorithm in established clinical sites demonstrating that LAM should be used in sites with high burden of HIV to improve the rapid diagnosis of TB.

Supporting information
S1 Fig. STARD flow diagram. Patient flow and Mtb culture (reference test) result.
(DOCX)
S1 Table. Absolute and relative frequencies of diagnostic tests at TB investigation by LAM result.
(DOCX)
S1 File. STARD checklist.
(DOCX)
S2 File. Data_LAM_final.
(CSV)
S3 File. Data_LAM_final.
(ZIP)
S4 File. Describe_LAM_final.
(TXT)

Author Contributions
Conceptualization: Leda Fátima Jamal, Denise Arakaki-Sanchez, Josué Nazareno de Lima, Maeve Brito de Mello, Pedro Emmanuel Alvarenga Americano do Brasil, Draurio Barreira, Valeria Rolla.
Data curation: Pedro Emmanuel Alvarenga Americano do Brasil.

Formal analysis: Pedro Emmanuel Alvarenga Americano do Brasil.

Funding acquisition: Denise Arakaki-Sanchez, Josué Nazareno de Lima, Maeve Brito de Mello, Draurio Barreira.

Investigation: Leda Fátima Jamal, Jose Henrique Pilotto, Francisco Ivanildo de Oliveira Junior, Tâmaria Newman Lobato Souza, Maria Cristina Lourenço.

Methodology: Pedro Emmanuel Alvarenga Americano do Brasil, Valeria Rolla.

Project administration: Aline Benjamin, Valeria Rolla.

Resources: Valeria Rolla.

Software: Pedro Emmanuel Alvarenga Americano do Brasil.

Supervision: Aline Benjamin, Leda Fátima Jamal, Valeria Rolla.

Writing – original draft: Aline Benjamin, Valeria Rolla.

Writing – review & editing: Solange Cesar Cavalcante, Leda Fátima Jamal, Jose Henrique Pilotto, Francisco Ivanildo de Oliveira Junior, Tâmaria Newman Lobato Souza, Pedro Emmanuel Alvarenga Americano do Brasil, Valeria Rolla.

References

1. N’Dhatz M, Domoua K, Coulibaly G, Traore F, Kanga K, Konan JB, et al. [Aspects of thoracic radiography of patients with tuberculosis and HIV infection in Ivory Coast]. Rev Pneumol Clin. 1994; 50: 317–322. PMID: 7701211

2. Murray JF. Pulmonary complications of HIV-1 infection among adults living in sub-Saharan Africa [State of the Art Series. HIV infection in low-income, high-burden settings, Edited by Murray JF. Number 4 in the series]. The International Journal of Tuberculosis and Lung Disease. 2005; 9: 826–835. PMID: 16104626

3. Elliott AM, Namaambo K, Allen BW, Luo N, Hayes RJ, Pobee JO, et al. Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tuber Lung Dis. 1993; 74: 191–194. https://doi.org/10.1016/0962-8479(93)90010-U PMID: 8369514

4. Johnson JL, Vjecho MJ, Okwera A, Hatanga E, Byekwaso F, Wolski K, et al. Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere University-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis. 1998; 2: 397–404. PMID: 9613636

5. Ministério da Saúde. Manual de recomendações para o controle da tuberculose no Brasil. Brasília/DF: Ministério da Saúde: Secretaria de Vigilância em Saúde: Departamento de Vigilância Epidemiológica; 2011.

6. Ministério da Saúde. Recomendações sobre o diagnóstico da tuberculose por meio do teste rápido molecular para tuberculose. Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância Epidemiológica; 2014.

7. Flores LL, Steingart KR, Dendukuri N, Schiller I, Minion J, Pai M, et al. Systematic Review and Meta-Analysis of Antigen Detection Tests for the Diagnosis of Tuberculosis. Clinical and Vaccine Immunology. 2011; 18: 1616–1627. https://doi.org/10.1128/CVI.05205-11 PMID: 21832100

8. Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. European Respiratory Journal. 2011; 38: 1398–1405. https://doi.org/10.1183/09031936.00025711 PMID: 21706061

9. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. The Lancet infectious diseases. 2012; 12: 201–209. https://doi.org/10.1016/S1473-3099(11) 70251-1 PMID: 22015305

10. World Health Organization P. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. [Internet]. Geneva, Switzerland; 2015. Available: http://www.who.int/entity/tb/areas-of-work/laboratory/policy_statement_lam_web.pdf?ua=1
11. Ministério da Saúde. Manual nacional de vigilância laboratorial da tuberculose e outras micobacterias. Brasília: Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância Epidemiológica; 2008.

12. Balcha TT, Winqvist N, Sturegård E, Skogmar S, Reepalu A, Jemal ZH, et al. Detection of lipoarabinomannan in urine for identification of active tuberculosis among HIV-positive adults in Ethiopian health centres. Trop Med Int Health. 2014; 19: 734–742. https://doi.org/10.1111/tmi.12308 PMID: 24684481

13. Peter JG, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, Kraus S, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J. 2012; 40: 1211–1220. https://doi.org/10.1183/09031936.00201711 PMID: 22362849

14. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, et al. Clinic-Based Urinary Lipoarabinomannan as a Biomarker of Clinical Disease Severity and Mortality Among Antiretroviral Therapy-Naïve Human Immunodeficiency Virus-Infected Adults in South Africa. Open Forum Infect Dis. 2017; 4. https://doi.org/10.1093/ofid/ofx167 PMID: 28979922

15. World Health Organization. Global tuberculosis report 2018. Geneva, Switzerland; 2018.

16. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine. 2010; 363: 1005–1015. https://doi.org/10.1056/NEJMoa0907847 PMID: 20825313

17. Ministério da Saúde. Rede de Teste Rápido para Tuberculose no Brasil: primeiro ano da implantação. Ministério da Saúde, Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis; 2015.

18. Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet. 2016; 387: 1187–1197. https://doi.org/10.1016/S0140-6736(15)01092-2 PMID: 26970721

19. Gupta-Wright A, Corbett EL, van Oosterhout JJ, Wilson D, Grint D, Alufandika-Moyo M, et al. Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial. The Lancet. 2018; 392: 292–301.

20. Ferreira Medeiros M, Jardim MR, Vital RT, Nery JA da C, Sales AM, de Moraes MO, et al. An Attempt to Improve Pure Neural Leprosy Diagnosis Using Immunohistochemistry Tests in Peripheral Nerve BiopsySpecimens: Applied Immunohistochemistry & Molecular Morphology. 2014; 22: 222–230. https://doi.org/10.1097/PAI.0b013e31828dc70c PMID: 23702646

21. Nahas AA, Lima MI de S, Goulart IMB, Goulart LR. Anti-Lipoarabinomannan-Specific Salivary IgA as Prognostic Marker for Leprosy Reactions in Patients and Cellular Immunity in Contacts. Frontiers in Immunology. 2018; 9. https://doi.org/10.3389/fimmu.2018.01205